From The Boston Globe · · 50s
GLP-1 Drugs Recalled Amid Safety Concerns
FDA recalls Apothecary Pharma's compounded GLP-1 injections after contamination risks.
In brief
FDA recalls Apothecary Pharma's compounded GLP-1 injections after contamination risks. FDA recalls 22 lots of Apothecary Pharma's compounded GLP-1 drugs due to contamination risks. Originally reported by The Boston Globe.
FDA Recall Announcement
FDA officials announced a nationwide recall of an injectable medication found in many compounded GLP-1 drugs.
Apothecary Pharma Recall
Apothecary Pharma LLC issued a voluntary recall on dozens of its tirzepatide injections on sept. 24.
Recall Scope
The recall impacts 22 lots of compounded GLP-1s, which are not FDA approved alternatives.
FDA's Safety Concerns
FDA warns compounded GLP-1s could contain contaminants including microbes and unapproved ingredients.
Recall Status Update
FDA classified the recall as presenting only a 'remote' possibility of serious health consequences.
Patient Guidance
FDA advises patients not to use compounded GLP-1s unless name-brand drugs cannot meet medical needs.
At a glance
FDA recalls 22 lots of Apothecary Pharma's compounded GLP-1 drugs due to contamination risks.
